“Regulatory pathways in oncology: ensuring novel anticancer medicines benefit patients”
Edward Cliff, MBBS, MPH, is an Australian haematology registrar with a passion for lymphoid malignancies (lymphoma and myeloma), novel immunotherapies, evidence-based medicine, clinical trial design & regulatory policy. He is currently a postdoctoral research fellow at the Program on Regulation, Therapeutics and Law (PORTAL), at Brigham and Women's Hospital and Harvard Medical School, working with Professor Aaron Kesselheim.
Eddie will review recent changes to regulatory approval pathways in oncology, with a focus on accelerated approval, the evidence thresholds used for oncology drug approval and novel cellular therapies.
Attend the event: Join virtual event